Lilly to Acquire Autoimmune Biotech Merida Biosciences
Eli Lilly signed a definitive agreement to acquire Merida Biosciences, developer of antibody-degrading biologics for autoimmune and allergic diseases, with lead candidate MER511 in Phase 1.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.